Jason Mitchell, MD, chief medical and clinical transformation officer, Presbyterian Healthcare Services, discusses which payment models have the most potential for succeeding in value-based care.
Jason Mitchell, MD, chief medical and clinical transformation officer, Presbyterian Healthcare Services, discusses which payment models have the most potential for succeeding in value-based care.
What payment models do you think have the most potential for succeeding in value-based care?
I think we’ve all been challenged with all of the different value-based payment models. There’s been a lot of experimentation, which is good. We want to experiment and iterate and see what works. I know that capitation works well. We use a lot of capitation within our organization, both for employed clinicians as well as independent clinicians, and that really moves the funding closer to where the patient is to the clinicians and the patients together. I think that’s a really successful model, but it’s not the only one, and not everyone is ready for capitation.
So, I think the work of accountable care organizations is helpful, if you look at bundled payment, that could be helpful, as well. If you look at the new announcement from CMS regarding primary care, they’re really looking at ways to allow primary care physicians to take some risk for Medicare fee-for-service, which is a great thing. Some folks want choice, so they aren’t doing Medicare Advantage HMO [health maintenance organization]; they’ll do fee-for-service, and that creates a place for us to experiment, as well.
I think there’s a lot of models and I think what we want to do as a nation, locally and nationally, is to continue to iterate, reinvent, and I joke about fail fast. Try it and if it doesn’t work, do something different and keep working on it. I’m not ascribed to any particular model, I think we just have to keep working on them.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More